ACADIA Pharmaceuticals Inc. (ACAD) Financial Ratios
26 years of historical data (2000–2025) · Healthcare · Biotechnology
EV/EBITDA
26.91
↑+138% vs avg
5yr avg: 11.29
30Y Low2.5·High11.3
P/FCF
36.74
↑+89% vs avg
5yr avg: 19.42
30Y Low19.4·High19.4
P/B Ratio
↓
3.15
↓-57% vs avg
5yr avg: 7.35
30Y Low0.6·High18.0
ROE
↑
39.9%
↓+1985% vs avg
5yr avg: -2.1%
30Y Low-139%·High72%
Debt/EBITDA
↑
0.38
↑+28% vs avg
5yr avg: 0.29
30Y Low0.0·High0.4
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ACAD Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
ACADIA Pharmaceuticals Inc. trades at 9.9x earnings, 27% below its 5-year average of 13.5x, sitting at the 50th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.3x, the stock trades at a discount of 56%. On a free-cash-flow basis, the stock trades at 36.7x P/FCF, 89% above the 5-year average of 19.4x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3.9B | — | $3.1B | $5.1B | $2.6B | $3.7B | $8.4B | $6.3B | $2.0B | $3.7B | $3.3B |
| Enterprise Value | $3.7B | — | $2.8B | $5.0B | $2.5B | $3.7B | $8.1B | $6.1B | $1.9B | $3.6B | $3.2B |
| P/E Ratio → | 9.85 | — | 13.49 | — | — | — | — | — | — | — | — |
| P/S Ratio | 3.61 | — | 3.19 | 7.06 | 4.98 | 7.74 | 19.04 | 18.57 | 9.15 | 29.56 | 192.80 |
| P/B Ratio | 3.15 | — | 4.17 | 11.88 | 6.43 | 6.93 | 13.41 | 9.01 | 4.27 | 11.01 | 6.45 |
| P/FCF | 36.74 | — | 19.42 | — | — | — | — | — | — | — | — |
| P/OCF | 35.17 | — | 19.36 | 307.10 | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ACAD EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
ACADIA Pharmaceuticals Inc.'s enterprise value stands at 26.9x EBITDA, 138% above its 5-year average of 11.3x. The Healthcare sector median is 14.4x, placing the stock at a 87% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 2.91 | 6.88 | 4.87 | 7.57 | 18.41 | 18.04 | 8.54 | 29.00 | 183.35 |
| EV / EBITDA | 26.91 | — | 11.29 | — | — | — | — | — | — | — | — |
| EV / EBIT | 35.66 | — | 33.05 | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | 17.72 | — | — | — | — | — | — | — | — |
ACAD Profitability
Margins and return-on-capital ratios measuring operating efficiency
ACADIA Pharmaceuticals Inc. earns an operating margin of 9.8%. Operating margins have expanded from -10.1% to 9.8% over the past 3 years, signaling improving operational efficiency. Return on equity of 39.9% is exceptionally high. ROIC of 10.0% represents solid returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 91.7% | 91.7% | 91.5% | 93.7% | 98.0% | 96.0% | 95.3% | 94.2% | 91.8% | 89.5% | 74.6% |
| Operating Margin | 9.8% | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% | -64.9% | -72.7% | -110.6% | -234.1% | -1574.1% |
| Net Profit Margin | 36.5% | 36.5% | 23.6% | -8.4% | -41.8% | -34.7% | -63.7% | -69.4% | -109.6% | -231.7% | -1565.9% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 39.9% | 39.9% | 38.9% | -14.7% | -45.9% | -28.7% | -42.5% | -39.9% | -60.2% | -67.8% | -75.6% |
| ROA | 28.4% | 28.4% | 23.4% | -9.2% | -33.5% | -22.6% | -36.0% | -35.6% | -53.0% | -61.2% | -69.3% |
| ROIC | 10.0% | 10.0% | 45.2% | -17.0% | -41.6% | -31.6% | -49.4% | -42.8% | -60.8% | -70.7% | -90.5% |
| ROCE | 10.1% | 10.1% | 35.8% | -15.3% | -41.9% | -26.6% | -41.4% | -41.5% | -60.6% | -68.5% | -75.9% |
ACAD Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
ACADIA Pharmaceuticals Inc. carries a Debt/EBITDA ratio of 0.4x, which is very conservative (89% below the sector average of 3.3x). The company holds a net cash position — cash of $178M exceeds total debt of $52M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.04 | 0.07 | 0.13 | 0.15 | 0.12 | 0.08 | 0.01 | — | — | — |
| Debt / EBITDA | 0.38 | 0.38 | 0.21 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.10 | -0.37 | -0.30 | -0.13 | -0.15 | -0.44 | -0.26 | -0.28 | -0.21 | -0.32 |
| Net Debt / EBITDA | -0.90 | -0.90 | -1.08 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -1.19 | -1.70 | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($178M) exceeds total debt ($52M)
ACAD Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
ACADIA Pharmaceuticals Inc.'s current ratio of 3.83x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.42x to 3.83x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.83 | 3.83 | 2.38 | 2.42 | 4.04 | 6.43 | 6.77 | 10.16 | 8.83 | 7.62 | 12.87 |
| Quick Ratio | 3.71 | 3.71 | 2.32 | 2.28 | 3.99 | 6.35 | 6.68 | 10.08 | 8.76 | 7.51 | 12.77 |
| Cash Ratio | 2.96 | 2.96 | 1.91 | 1.73 | 3.32 | 5.42 | 5.96 | 9.32 | 7.95 | 6.96 | 12.42 |
| Asset Turnover | — | 0.69 | 0.81 | 0.97 | 0.88 | 0.69 | 0.56 | 0.43 | 0.41 | 0.32 | 0.03 |
| Inventory Turnover | 2.57 | 2.57 | 3.73 | 1.28 | 1.53 | 2.43 | 2.12 | 3.09 | 4.50 | 2.49 | 1.06 |
| Days Sales Outstanding | — | 50.49 | 39.90 | 51.43 | 44.51 | 49.26 | 41.55 | 40.77 | 45.32 | 53.86 | 150.37 |
ACAD Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
ACADIA Pharmaceuticals Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 10.1% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 10.1% | — | 7.4% | — | — | — | — | — | — | — | — |
| FCF Yield | 2.7% | — | 5.1% | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $171M | $166M | $164M | $162M | $160M | $157M | $147M | $127M | $123M | $116M |
Peer Comparison
Compare ACAD with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ACADYou | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 AXSM | $11B | -59.8 | — | — | 92.6% | -26.5% | -252.1% | -1906.7% | — |
 INTR | $3B | 11.4 | 17.3 | 4.9 | 42.4% | 10.9% | 13.2% | 3.9% | 15.4 |
 PTCT | $5B | 8.3 | 5.4 | 7.6 | 95.9% | 49.5% | — | — | 0.5 |
 BIIB | $28B | 21.7 | 11.4 | 13.8 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
 ALKS | $6B | 24.8 | 17.3 | 12.3 | 86.7% | 17.2% | 14.7% | 18.9% | 0.2 |
 SUPN | $3B | -76.9 | 53.4 | 65.5 | 89.6% | -5.1% | -3.7% | -2.8% | 0.7 |
 JAZZ | $14B | -38.9 | 23.8 | 11.0 | 88.2% | 5.3% | -8.5% | 2.1% | 7.1 |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 25 years · Updated daily
See ACAD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ACAD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ACAD vs INVA
Side-by-side business, growth, and profitability comparison vs Innoviva, Inc..
Start ComparisonACAD — Frequently Asked Questions
Quick answers to the most common questions about buying ACAD stock.
What is ACADIA Pharmaceuticals Inc.'s P/E ratio?
ACADIA Pharmaceuticals Inc.'s current P/E ratio is 9.9x. The historical average is 8.3x. This places it at the 50th percentile of its historical range.
What is ACADIA Pharmaceuticals Inc.'s EV/EBITDA?
ACADIA Pharmaceuticals Inc.'s current EV/EBITDA is 26.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 6.9x.
What is ACADIA Pharmaceuticals Inc.'s ROE?
ACADIA Pharmaceuticals Inc.'s return on equity (ROE) is 39.9%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -46.5%.
Is ACAD stock overvalued?
Based on historical data, ACADIA Pharmaceuticals Inc. is trading at a P/E of 9.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are ACADIA Pharmaceuticals Inc.'s profit margins?
ACADIA Pharmaceuticals Inc. has 91.7% gross margin and 9.8% operating margin.
How much debt does ACADIA Pharmaceuticals Inc. have?
ACADIA Pharmaceuticals Inc.'s Debt/EBITDA ratio is 0.4x, indicating low leverage. A ratio below 2x is generally considered financially healthy.